Kenneth J. Snow, M.D., Chief Medical Officer of NeuroMetrix, Inc. Interviewed by KIDELA TVWALTHAM, Mass.
--(BUSINESS WIRE)--Jul. 19, 2012--
(Nasdaq: NURO), www.neurometrix.com
a medical device company focused on the diagnosis and treatment of the
neurological complications of diabetes, reported today that its Chief
Medical Officer was interviewed by KIDELA TV, a financial news network.
The interview is available at: http://www.youtube.com/watch?v=6xY0jmYk44M&feature=youtu.be
In the interview, Dr. Snow discusses some of the complications of
diabetes including diabetic peripheral neuropathy or DPN. DPN is the
most common chronic complication of diabetes affecting over 50% of
people with diabetes. It can lead to costly and debilitating foot ulcers
and, ultimately, to amputation. Early detection provides the opportunity
for clinical intervention and behavior modification which may moderate
the effects of DPN. NeuroMetrix markets a medical device, NC-stat®
DPNCheck™, which provides a fast, accurate, quantitative and
cost effective test for the early detection of systemic neuropathies,
such as DPN.
Dr. Snow, a practicing endocrinologist, notes that NC-stat DPNCheck is a
significant advance over the tools historically available for detection
of DPN. These tools include the monofilament and the tuning fork which
detect DPN only at a late stage where a patient may already have lost
protective sensation in his feet. Dr. Snow also comments on the
correlation between DPN and risk of cardiac disease, as well as on the
benefits in reinforcing patient compliance.
Dr. Snow has extensive experience in the field of diabetes, including
patient care and clinical research. Prior to joining NeuroMetrix, he
spent the 17 years at the Joslin Diabetes Center in Boston, MA which is
affiliated with Harvard Medical School and is considered the world's
oldest and most respected diabetes care facility. Most recently, Dr.
Snow was Director of Medical Programs at the Joslin Center for Strategic
Initiatives and previously was Acting Chief of the Adult Diabetes
Section at the Joslin. Dr. Snow also holds an appointment as Assistant
Professor of Medicine at Harvard Medical School.
A business profile of NeuroMetrix is available at: http://www.kidela.com/members/neurometrix45/
NeuroMetrix is an innovative medical device company that develops and
markets home use and point-of-care devices, associated consumables, and
support software for the treatment and management of diabetes and its
complications. The company is focused on nerve related complications of
diabetes, called diabetic neuropathies, which affect over 50% of people
with diabetes. If left untreated, diabetic neuropathies trigger foot
ulcers that may require amputation, cause disabling chronic pain, and
increase the risk of falling in the elderly. The annual cost of diabetic
neuropathies has been estimated at $14 billion in the United States. The
company’s products are used by physicians and other clinicians, in
retail health settings such as pharmacies, and by managed care
organizations to optimize patient care and reduce healthcare costs. The
company markets the NC-stat® DPNCheck™ device,
which is a rapid, accurate, and quantitative point-of-care test for
diabetic neuropathy. This product is used to detect diabetic neuropathy
at an early stage and to guide treatment. The company is in late stage
development of SENSUS™, a pain management device. The company
has additional therapeutic products in its pipeline. For more
information, please visit http://www.neurometrix.com.
Source: NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
Chief Financial Officer